Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BG 1805

Next Previous
Drug Profile

BG 1805

Alternative Names: BG-1805

Latest Information Update: 08 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Bio-gene Technology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia

Most Recent Events

  • 08 Apr 2024 BG 1805 is still in phase I trials for Acute myeloid leukaemia in China (IV) (Guangzhou Bio-gene Technology pipeline, April 2024)
  • 07 Mar 2024 Phase-I/II clinical trials in Acute myeloid leukaemia (In adults, In the elderly, Second-line therapy or greater) in China (IV) (NCT06118788)
  • 28 Jan 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(In children, Second-line therapy or greater) in China (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top